Eris Lifesciences Limited has announced its participation in an upcoming investor conference with Capital Group, scheduled for March 19, 2026. The announcement was made on March 13, 2026, in compliance with Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

Meeting Details

The investor meeting is structured as follows:

Regulatory Compliance

The company has emphasized its commitment to regulatory compliance by making this announcement under SEBI's listing regulations. Eris Lifesciences has specifically noted that the schedule is indicative and subject to changes due to any unforeseen developments.

The company has also clarified its approach to information sharing during the meeting. Management will refer only to publicly available documents for discussions during the interaction, ensuring that no unpublished price sensitive information (UPSI) will be discussed during the meeting.

Company Leadership

The announcement was signed by Milind Talegaonkar, Company Secretary & Compliance Officer (Membership No: A26493), who digitally signed the document on March 13, 2026. The company maintains its registered and corporate office at Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054.

This investor meeting represents part of Eris Lifesciences' ongoing engagement with institutional investors and analysts as part of its investor relations activities.

Eris lifesciences Limited has completed the allotment of 19,624 equity shares on March 12, 2026, under its Employee Stock Option Plan (ESOP-2021) scheme. The pharmaceutical company informed both BSE Limited and National Stock Exchange of India Limited about this corporate action through an official communication.

ESOP Allotment Details

The allotment encompasses shares from employee stock options granted across three consecutive years under the ESOP-2021 scheme. The breakdown demonstrates varying exercise prices reflecting different grant periods and market conditions at the time of grant.

Impact on Share Capital

The allotment has resulted in an increase in the company's paid-up share capital structure. The capital expansion reflects the conversion of employee stock options into equity shares, which is a standard practice under ESOP schemes.

Corporate Communication

The allotment information was communicated to the stock exchanges by Milind Talegaonkar, Company Secretary and Compliance Officer, as part of the company's regulatory disclosure obligations. The communication was digitally signed and dated March 12, 2026, ensuring proper documentation and compliance with exchange requirements.

This ESOP exercise represents the conversion of employee stock options into equity shares, allowing eligible employees to become shareholders in the pharmaceutical company. The varying exercise prices across different grant years reflect the market conditions and company valuation at the respective times of grant under the ESOP-2021 scheme.